Successfully began trading on NASDAQ under ticker TTRX on October 8, 2025 Strengthened its Board of Directors with the appointments of Arthur Golden and Dr. Kent Kester Entered into a global supply, development, and license agreement with leading medical-surgical product manufacturer and distributor Medline LOS ANGELES, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing dermatologic, advanced wound, and infectious disease therapies, t ...

Core Viewpoint - Turn Therapeutics (TTRX.US) stock price surged over 144%, reaching $16.95, indicating strong market interest and potential investor confidence in the company's innovative therapies [1] Company Overview - Turn Therapeutics focuses on developing next-generation therapies for skin diseases, wounds, and infections [1] - The company utilizes a proprietary delivery platform technology called "PermaFusion®" [1] Technology and Innovation - The "PermaFusion®" technology allows water-soluble active ingredients to penetrate the skin, nails, or mucous membranes using an oil-based carrier without the need for emulsifiers [1] - This technology aims to enhance the availability of active ingredients while reducing irritation [1]